Olema Pharmaceuticals, Inc. (OLMA): Shareholders' Equity
$478.56M
As of 2025-12-31
$430.56M
As of 2026-06-30
+34.3%
3-year compound annual growth
+7.2%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $478.56M | +17.0% | 2026-03-16, Balance as of period end |
| 2024-12-31 | $408.96M | +61.1% | 2026-03-16, Balance as of period end |
| 2023-12-31 | $253.90M | +28.5% | 2025-03-18, Balance as of period end |
| 2022-12-31 | $197.55M | -30.6% | 2024-03-11, Balance as of period end |
| 2021-12-31 | $284.57M | -15.8% | 2023-03-09, Balance as of period end |
| 2020-12-31 | $338.14M | n/m | 2022-02-28, Balance as of period end |
| 2019-12-31 | -$10.59M | n/a | 2022-02-28, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | 2025-12-31 | $478.56M | +17.0% |
| Dianthus Therapeutics, Inc. (DNTH) | 2025-12-31 | $493.40M | +40.0% |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $64.63M | -77.6% |
| Edgewise Therapeutics, Inc. (EWTX) | 2025-12-31 | $522.26M | +13.7% |
| Rigel Pharmaceuticals Inc (RIGL) | 2025-12-31 | $391.48M | n/m |
| Rapport Therapeutics, Inc. (RAPP) | 2025-12-31 | $484.65M | +58.7% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $166.95M | -3.7% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $424.29M | -10.1% |
| Geron Corp (GERN) | 2025-12-31 | $225.87M | -19.4% |
Compare OLMA, DNTH, SNDX, EWTX side by side · Screen every company in Pharmaceutical Preparations ↗